helmapren susp. - Lomus Pharmaceuticals Pvt. Ltd.

HELMAPREN Tablet/ SuspensionsDosage Forms/CompositionEach Tablet contains Albendazole 400 mgEach 5 ml contains 200 mgPharmacological IndexAnthelminticINDICATIONTreatment of parenchymal neurocysticercosis and cystic hydatid disease of the liver,lung, and peritoneum; albendazole has activity against Ascaris lumbricoides(roundworm), Ancylostoma duodenale and Necator americanus (hookworms),Enterobius vermicularis (pinworm), Hymenolepis nana and Taenia sp (tapeworms),Opisthorchis sinensis and Opisthorchis viverrini (liver flukes), Strongyloides stercoralisand Trichuris trichiura (whipworm); activity has also been shown against the liver flukeClonorchis sinensis, Giardia lamblia, Cysticercus cellulosae, Echinococcus granulosus,Echinococcus multilocularis, and Toxocara sp.Pregnancy Risk FactorCContraindicationsPatients with hypersensitivity to albendazole or its components; pregnant women, ifpossibleWarnings/PrecautionsDiscontinue therapy if LFT elevations are significant; may restart treatment whendecreased to pretreatment values. Becoming pregnant within 1 month followingtherapy is not advised. Corticosteroids should be administered 1-2 days beforealbendazole therapy in patients with neurocysticercosis to minimize inflammatoryreactions and steroid and anticonvulsant therapy should be used concurrently duringthe first week of therapy for neurocysticercosis to prevent cerebral hypertension. Ifretinal lesions exist in patients with neurocysticercosis, weigh risk of further retinaldamage due to albendazole-induced changes to the retinal lesion vs benefit of diseasetreatment.Adverse ReactionsN = neurocysticercosis; H = hydatid diseaseDermatologic: Alopecia/rash/urticaria (

Drug InteractionsMay inhibit CYP1A2 enzyme (mild)Increased effect: Dexamethasone increases plasma levels of albendazole metabolites;praziquantel may increase plasma concentrations of albendazole by 50%; albendazoleinhibits hepatic cytochrome P-450 1A and may consequently interact by increasing theconcentrations of many drugs which are metabolized by this route; food (especiallyfatty meals) increases the oral bioavailability by 4-5 timesMechanism of ActionActive metabolite, albendazole, causes selective degeneration of cytoplasmicmicrotubules in intestinal and tegmental cells of intestinal helminths and larvae;glycogen is depleted, glucose uptake and cholinesterase secretion are impaired, anddesecratory substances accumulate intracellulary. ATP production decreases causingenergy depletion, immobilization, and worm death.Pharmacodynamics/KineticsAbsorption: Oral absorption is poor (

greater than or equal to 60 kg: 400 mg twice daily for 3 cycles as aboveStrongyloidiasis/tapeworm:less than or equal to 2 years: 200 mg/day for 3 days; may repeat in 3 weeks>2 years and Adults: 400 mg/day for 3 days; may repeat in 3 weeksGiardiasis: Adults: 400 mg/day for 3 daysHookworm, pinworm, roundworm:less than or equal to 2 years: 200 mg as a single dose; may repeat in 3 weeks>2 years and Adults: 400 mg as a single dose; may repeat in 3 weeksPatient InformationTake according to prescribed dosage schedule with meals. You may experience loss ofhair (reversible); dizziness or headaches (use caution when driving or engaging intasks that require alertness until response to drug is known). Report unusual fever,abdominal pain, unresolved vomiting, yellowing of skin or eyes, darkening of urine, orlight colored stools. Pregnancy/breast-feeding precautions: Inform prescriber if youare or intend to be pregnant. Breast-feeding is not recommended.LOMUS Drug Information CenterLomus Pharmaceuticals Pvt. Ltd.P.O. Box No 4506, Lomus House (Corporate office),Kailash Chour, Lazimpat, Kathmandu, NepalPh: 4436396 (Hunting Line). Fx: 977-1-4436395E-mail: druginfo@lomus.com.np